Bradda Head Lithium Ltd has reported visible spodumene mineralisation in all three initial drill holes at its Whistlejacket lithium project in Arizona. Key intersections include 31.8 meters and 46 meters of spodumene-bearing rock, indicating promising continuity and size of the lithium system. While these visual results are preliminary and not definitive of grade or true width, they build on previous positive drilling by Kennecott. Assay results from the first hole are expected soon, with further drilling ongoing as part of a planned 24-hole program in 2026, potentially advancing the project's development prospects.
Bradda Head Lithium drilling results provide context for readers. For those tracking Basic Materials, 21 of 38 US stocks rose and 17 fell on Pluang. Notable prices as of Oct 05, 2026 14:11 WIB include DuPont de Nemours Inc at USD 130.77, Standard Lithium Ltd at USD 1.75, and CF Industries Holdings, Inc. at USD 114.59.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
